T8541 |
Lenvatinib mesylate
|
857890-39-2
|
99.79%
|
|
Lenvatinib mesylate is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
|
T0520 |
Lenvatinib
|
417716-92-8
|
99.8000%
|
|
Lenvatinib is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor Tyrosine Kinase Inhibitor.
|
T0093 |
Sorafenib tosylate
|
475207-59-1
|
99.81%
|
|
Sorafenib is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).
|
T7861 |
Flumatinib mesylate
|
895519-91-2
|
99.82%
|
|
Flumatinib mesylate is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.
|
T1895 |
SKLB 610
|
1125780-41-7
|
99.83%
|
|
SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2, and PDGFR at a rate of 97%, 65%, and 55%, respectively, a...
|
T6920 |
ON123300
|
1357470-29-1
|
99.84%
|
|
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
|
T0097L |
Pazopanib
|
444731-52-6
|
99.84%
|
|
Pazopanib, a small molecule inhibitor, inhibits multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits VEGFR-1,...
|
T1792 |
Regorafenib
|
755037-03-7
|
99.87%
|
|
Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5/2.5/4.2/7/13/22 nM for RET/C-RAF/VEGFR2/c-Kit/VEGFR1/PDGFRβ).
|
T60110 |
KN1022
|
205255-11-4
|
99.88%
|
|
KN1022 is an inhibitor of phosphorylation of platelet-derived growth factor (PDGF) receptor with IC50 of 0.26 μM.
|
T0093L |
Sorafenib
|
284461-73-0
|
99.89%
|
|
Sorafenib is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-4/B-Raf).
|
T2446 |
KI8751
|
228559-41-9
|
99.9%
|
|
KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.
|
T2609 |
Masitinib
|
790299-79-5
|
99.91%
|
|
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has ...
|
T1777 |
Nintedanib
|
656247-17-5
|
99.92%
|
|
Nintedanib is an inhibitor of the receptor tyrosine kinases VEGFR/FGFR/PDGFR (IC50s: 13-34/37-610/59/65 nM for VEGFR1-3, FGFR1-4, and PDGFRα/β, respectively).
|
T8544 |
Masitinib mesylate
|
1048007-93-7
|
99.92%
|
|
Masitinib mesylate is a selective and orally bioavailable c-Kit inhibitor (IC50 of 200 nM,540/800 nM,510 nM for human recombinant c-Kit;PDGFRα/β;LynB,respectivel...
|
T6230 |
Imatinib
|
152459-95-5
|
99.94%
|
|
matinib is an inhibitor of the receptor tyrosine kinases c-Abl, Bcr-Abl, PDGFR, and c-Kit (IC50: 600/100/100 nM).
|
T2500 |
Cediranib
|
288383-20-0
|
99.94%
|
|
Cediranib (AZD2171) is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro, also inhibits Flt1/4 (IC50: 5 nM/...
|
T4320 |
Flumatinib
|
895519-90-1
|
99.95%
|
|
Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
|
T0080 |
Trapidil
|
15421-84-8
|
99.96%
|
|
Trapidil is a coronary vasodilator agent. It was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic ...
|
T5001 |
Nintedanib esylate
|
656247-18-6
|
99.96%
|
|
BIBF 1120 esylate is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β
|
TN2354 |
Methylnissolin
|
73340-41-7
|
99.98%
|
|
3-Hydroxy-9,10-dimethoxyptercarpan is derived from Astragalus and has antibacterial and anti-cancer effects.
|